Dr. Santa-Maria is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Skip Viragh Outpatient Cancer Center
201 N Broadway
Baltimore, MD 21287Phone+1 410-955-8893- Is this information wrong?
Summary
- Dr. Cesar Santa-Maria is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Sibley Memorial Hospital. He received his medical degree from McGovern Medical School at UTHealth and has been in practice 16 years. He specializes in breast cancer and is experienced in immunotherapy, breast cancer, and clinical research. He has more than 60 publications and over 500 citings.
Education & Training
NorthwesternMSCI, 2015 - 2017
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2008 - 2011
McGovern Medical School at UTHealthClass of 2004
Certifications & Licensure
MD State Medical License 2011 - 2025
DC State Medical License 2019 - 2024
NC State Medical License 2020 - 2022
IL State Medical License 2014 - 2020- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer Start of enrollment: 2018 Nov 13
- Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer Start of enrollment: 2021 Jul 21
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.Taylor, B., Sun, X., Gonzalez-Ericsson, P., Sanchez, V., Sanders, M., Wescott, E., Opalenik, S., Hanna, A., Chou, S., Van Kaer, L., Gomez, H., Isaacs, C., Ballinger, T...> ;Cancer Discovery. 2024 Feb 8
- Spatial and Compositional Biomarkers in Tumor Microenvironment Predicts Clinical Outcomes in Triple-Negative Breast Cancer.Mi, H., Varadhan, R., Cimino-Mathews, A., Popel, A., Emens, L., Santa-Maria, C.> ;Biorxiv. 2023 Dec 20
- 1 citationsAtezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical...Lehmann, B., Abramson, V., Dees, E., Shah, P., Ballinger, T., Isaacs, C., Santa-Maria, C., An, H., Gonzalez-Ericsson, P., Sanders, M., Newsom, K., Abramson, R., Sheng,...> ;JAMA Oncology. 2024 Feb 1
- Join now to see all
Press Mentions
Behind the Study: Weight Loss Strategies for Breast Cancer SurvivorsMarch 3rd, 2022- Dr. Vered Stearns, Oncologist at Johns Hopkins, Is on the Cutting Edge of Breast Cancer ResearchOctober 27th, 2021
Test All Triple Negative Breast Cancer Patients for PD-L1June 29th, 2019
Professional Memberships
- Member
- Member
Hospital Affiliations
Johns Hopkins HospitalBaltimore, Maryland
Sibley Memorial HospitalWashington, District of Columbia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
